Abstract: SA-PO456
Long-Term SARS-CoV-2 Antibody Titers After mRNA Vaccination in Patients Undergoing Hemodialysis in Japan
Session Information
- Hemodialysis and Frequent Dialysis: Clearance, Technology, Infection
November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Kanai, Daisuke, Yokohama Shiritsu Daigaku Igakubu Daigakuin Igaku Kenkyuka, Yokohama, Kanagawa, Japan
- Haze, Tatsuya, Yokohama Shiritsu Daigaku Igakubu Daigakuin Igaku Kenkyuka, Yokohama, Kanagawa, Japan
- Wakui, Hiromichi, Yokohama Shiritsu Daigaku Igakubu Daigakuin Igaku Kenkyuka, Yokohama, Kanagawa, Japan
- Hanaoka, Masaaki, Iryo Hojin Shadan Kohsaikai Kamioooka Jinsei Clinic, Yokohama, Japan
- Abe, Eriko, Yokohama Shiritsu Daigaku Igakubu Daigakuin Igaku Kenkyuka, Yokohama, Kanagawa, Japan
- Azushima, Kengo, Yokohama Shiritsu Daigaku Igakubu Daigakuin Igaku Kenkyuka, Yokohama, Kanagawa, Japan
- Hirawa, Nobuhito, Yokohama Shiritsu Daigaku Fuzoku Shimin Sogo Iryo Center, Yokohama, Kanagawa, Japan
- Tamura, Kouichi, Yokohama Shiritsu Daigaku Igakubu Daigakuin Igaku Kenkyuka, Yokohama, Kanagawa, Japan
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is shown to prevent severe illness and death in hemodialysis (HD) patients, but the immune response to vaccines is reduced in this population. This study compares SARS-CoV-2 spike protein antibody titers between HD patients and healthy controls in Japan for up to 6 months following vaccination.
Methods
A multi-institutional retrospective study at five clinics in Japan was conducted using 412 HD patients and 156 healthy controls who received two doses of the BNT162b2 (Pfizer-BioNTech) mRNA vaccine. Anti- SARS-CoV-2 spike protein S1 IgG antibody titers were measured at 1, 3, and 6 months after the second dose. The attenuation speed was calculated as slope (i.e., –b) by using a linear mixed-effects model toward the log-transformed antibody titers.
Results
The HD group had significantly lower month 1 antibody titers (Ab-titer-1) than the controls, and these remained lower through month 6 (95% CI: 2617.1 (1296.7, 5240.8) vs. 7285.4 (4403.9, 11000.0) AU/mL at Ab-titer-1, and 353.4 (178.4, 656.3) vs. 812.0 (498.3, 1342.7) AU/mL at Ab-titer-6 (p <0.001, respectively)). Lower log Ab-titer-1 levels in the HD group were significantly associated with a lower log Ab-titer-6 (0.90 [0.83, 0.97], p <0.001). The –b values in the HD patients and healthy controls were –4.7 ± 1.1 and –4.7 ± 1.4 (year-1), respectively. In the HD patient group, age, serum albumin level, and hemoglobin level showed a negative correlation with Ab-titer-1, and the use of vitamin D preparation showed a positive correlation. In addition, the lower peak antibody titer contributed to the lower Ab-titer-6.
Conclusion
SARS-CoV-2 spike protein antibody titers were significantly lower in HD patients than in healthy controls at 1 (peak) and 6 months after the second vaccination. Low peak antibody titers contributed to low 6-month antibody titers.